Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Group 1 - Genelux Corporation announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at $3.50 per share, expecting gross proceeds of$10.5 million before deductions [1][2] - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including the continued clinical development of Olvi-Vec [2] - The offering is expected to close on or about March 26, 2025, subject to customary closing conditions [2] Group 2 - Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [4] - Olvi-Vec is currently being evaluated in two U.S.-based clinical trials: a Phase 3 trial for platinum-resistant ovarian cancer and a Phase 2 trial for non-small-cell lung cancer [4] - The company utilizes its proprietary CHOICE™ platform to develop an extensive library of oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec [4]